DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

DVA·DaVita Inc.

$.
+. (+.%)
After Hours
High
$237.32
Open
$231.72
Market Cap
15.17B
52W High
$239.64
Low
$231.72
P. Close
$234.14
P/E
19.41
52W Low
$101.00
Fwd P/E
13.59
DailyIQ Est.
$204.11
Technical Score (1D)
91
BUY
News Sentiment
77
BULLISH
A recent dip in the broader market lifted DVA, as the stock closed at $234.01, suggesting the move was largely driven by general market dynamics rather than company‑specific catalysts. The lack of new company announcements means the price action is likely a short‑term reaction to overall market sentiment. In the next 1–10 trading days, DVA’s performance will largely mirror the broader market’s direction, with any significant deviation potentially signaling sector‑specific news. Traders should watch for the company’s upcoming earnings report, which could provide fresh guidance or highlight operational changes. Regulatory developments in the dialysis sector, such as Medicare reimbursement adjustments, remain a key watch item that could materially affect DVA’s valuation. Additionally, macroeconomic factors like rising interest rates could influence the cost of capital for dialysis providers, impacting DVA’s growth prospects. The company’s exposure to Medicare patients means that any shifts in federal healthcare policy could have a pronounced effect on its revenue stream. Monitoring the broader healthcare index for similar movements can help gauge whether DVA’s recent lift is part of a sector‑wide trend. Finally, keeping an eye on any FDA or CMS updates related to dialysis technology or reimbursement will be crucial for anticipating potential catalysts.
Earnings Summary
DaVita Inc. is a leading provider of kidney dialysis services in the United States, operating outpatient dialysis centers and offering inpatient, home‑based, and laboratory services as part of a comprehensive kidney‑care platform. The company’s business is anchored in the medical‑care‑facilities sector, where reimbursement dynamics and patient volume drive performance. In the most recent quarters, DaVita’s Q4 2024 earnings surpassed expectations with an EPS of $2.24 versus a $2.13 estimate and revenue of $3.295 billion, while Q1 2025 saw a modest EPS miss at $2.00 against a $2.02 estimate and revenue of $3.224 billion; Q2 2025 reversed the trend with an EPS of $2.95 beating a $2.75 estimate and revenue of $3.380 billion, but Q3 2025 recorded an EPS of $2.51 below a $3.17 estimate despite revenue of $3.420 billion; Q1 2026 again beat expectations with an EPS of $2.87 versus $2.33 and revenue of $3.416 billion versus a $3.356 billion estimate. Over the past year, revenue has fluctuated, rising from $3.295 billion in Q4 2024 to $3.420 billion in Q3 2025 before settling near $3.416 billion in Q1 2026, while EPS has oscillated between $2.00 and $2.95, indicating a pattern of earnings volatility amid steady revenue growth. Recent news highlights a Barclays price‑target upgrade to $218, a Zacks Rank #1 growth designation, and the rollout of AI‑driven scheduling tools that could enhance operational efficiency; these developments underscore market confidence in DaVita’s growth trajectory and potential margin improvement. Investors should watch for the Q2 2026 earnings release to confirm guidance, monitor regulatory updates that could affect Medicare reimbursement rates, and assess the pace of AI tool deployment, as these factors will be key to sustaining the company’s earnings momentum.

EPS

EstBeatMiss
$1.72$2.33$2.94$3.55$4.16Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.88 - -
Q1'26$2.33$2.87+23.2%
Q3'25$3.17$2.51-20.9%
Q2'25$2.75$2.95+7.3%
Q1'25$2.02$2.00-1.0%
Q4'24$2.13$2.24+5.4%

Revenue

EstBeatMiss
$3.2B$3.3B$3.4B$3.5B$3.6BQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.5B - -
Q1'26$3.4B$3.4B+1.8%
Q3'25 - $3.4B -
Q2'25 - $3.4B -
Q1'25 - $3.2B -
Q4'24 - $3.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DVA Stock Snapshot

DVA is currently trading at $234.01, giving DaVita Inc. a market cap of 15.17B and a P/E ratio of 19.4. Today's range spans $231.72–$237.32, with shares opening at $231.72 and moving down $0.13 (0.1%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 77/100.

Over the past year DVA has traded between $101.00 and $239.64 - the current price is +131.7% off the 52-week low and -2.3% from the high. 14 analysts cover the stock with a Hold consensus and a mean 12-month target of $202.14 (range $145.00–$270.00), implying downside of -13.6%.

The combination of bullish technicals and bullish sentiment for DaVita Inc. (DVA) is the kind of setup that shows up in systematic screens before the more discretionary investors arrive. Score 91/100 (BUY), price $234.01 (near 52-week highs), sentiment 77/100. The current P/E ratio stands at 19.4. At 15.17B in Healthcare market cap, this large-cap name has the right size to matter to a wide range of buyers. Annual range: $101.00–$239.64.

What makes DVA's BUY setup (91/100) particularly actionable at 15.17B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $234.01 (near 52-week highs in $101.00–$239.64), with sentiment running bullish at 77/100, the setup rewards conviction-sized positioning more than it does speculative small bets.